ArticleFrontiers in neurology2019
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease.
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease.Frontiers in neurology · 2021Pooled it
- Thalamic nuclei insights into Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Targeting p75NTR activity alleviates the neurotoxic effect of high glucose on iPSC-derived dopaminergic neurons.Stem cell research & therapy · 2026Article
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Predictive value of cerebrospinal fluid Alzheimer's disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson's disease.Brain communications · 2026Article
- Parkinson's Disease: Immunometabolic Control Points Across Neural, Vascular, and Peripheral Systems.Parkinson's disease · 2026Review
- The ketogenic diet in Parkinson's disease: a potential therapeutic strategy.Pharmacological reports : PR · 2025Review
- Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD.Annals of clinical and translational neurology · 2025Article
- Impact of 6-OHDA injection and microtrauma in the ratHistology and histopathology · 2025Article
- Unraveling the interplay of β-amyloid pathology and Parkinson's disease progression: Insights from autopsy-confirmed patients.Heliyon · 2024Article
- Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson's Disease.Nuclear medicine and molecular imaging · 2024Review
- Deep Learning-Driven Estimation of Centiloid Scales from Amyloid PET Images withBrain sciences · 2024Article
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study.The journal of prevention of Alzheimer's disease · 2024Article
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?International journal of molecular sciences · 2023Review
- Age-related hearing loss and dementia-related neuropathology: An analysis of the United Kingdom brains for dementia research cohort.Brain pathology (Zurich, Switzerland) · 2023Article
- Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:IBRO neuroscience reports · 2023Article
- Acquired Stuttering in Parkinson's Disease.Movement disorders clinical practice · 2023Article
- The consequences of sleep deprivation on cognitive performance.Neurosciences (Riyadh, Saudi Arabia) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.